Far Infrared Treatment for Alzheimer's Disease
|ClinicalTrials.gov Identifier: NCT00599469|
Recruitment Status : Unknown
Verified August 2009 by GAAD Medical Research Institute Inc..
Recruitment status was: Active, not recruiting
First Posted : January 23, 2008
Last Update Posted : August 17, 2009
|Condition or disease||Intervention/treatment||Phase|
|Alzheimer Disease||Radiation: Far Infrared Radiation (5μm to 20μm wavelength)||Phase 1|
Alzheimer's destroys brain cells, causing problems with memory, thinking and behaviour severe enough to affect work, lifelong hobbies or social life. Alzheimer's gets worse over time and it is fatal.
Alzheimer's, which has no current cure, is the most common form of dementia. It is hereby postulated that far infrared radiation of the central nervous and endocrine systems will help with the management of the disease and possibly cure the disease.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||4 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for the Treatment of Alzheimer's Disease.|
|Study Start Date :||February 2008|
|Estimated Primary Completion Date :||March 2009|
|Estimated Study Completion Date :||April 2009|
Far Infrared Radiation
Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
Far Infrared radiation for 30 to 40 minutes per treatment session.
- Management and Cure of Alzheimer's Disease [ Time Frame: 1 year ]
- Management and Cure of Dementia [ Time Frame: 1 year ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00599469
|The Centre for Incurable Diseases|
|Toronto, Ontario, Canada, M4V 1L5|
|Principal Investigator:||Ken Nedd, M.D.||GAAD Medical Research Institute Inc.|
|Study Director:||Kwasi Donyina, Ph.D.||GAAD Medical Research Institute Inc.|